APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorZhejiang University
About this trial
A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma
Eligibility criteria
Qualifiers
Histologically confirmed diagnosis of BCMA/TACI+ multiple myeloma (MM)：
Patients with MM relapsed after BCMA CAR-T therapy; Or MM with positive BCMA/TACI expression;
Relapsed after hematopoietic stem cell transplantation;
Cases with recurrent positive minimal residual disease;
Disqualifiers
History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;
Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
Pregnant (or lactating) women;
Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
Trial design
Treatments tested in this trial
- APRIL CAR-T cells
Treatment groups
36 Participants
are divided into 1 treatment groupSponsors and collaborators
Zhejiang University
Lead sponsor
Yake Biotechnology Ltd.
Collaborator
Source ClinicalTrials.gov